We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.14 | -0.35% | 39.87 | 1,155 | 09:04:30 |
From Jul 2022 to Jul 2024
2:14 p.m. ET -- GSK is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The European Commission on Wednesday European Commission has authorized the company's Arexvy, a respiratory syncytial virus vaccine, for use in Europe. GSK said RSV, a common, contagious respiratory virus, leads to over 270,000 hospitalizations and about 20,000 in-hospital deaths each year in adults aged 60 years and over in Europe. Dow Jones & Co. owns Factiva. (stephen.nakrosis@wsj.com)
(END) Dow Jones Newswires
June 07, 2023 14:30 ET (18:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
